Goldman Sachs Group Inc Bria Cell Therapeutics Corp. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Bria Cell Therapeutics Corp. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 94,200 shares of BCTX stock, worth $476,651. This represents 0.0% of its overall portfolio holdings.
Number of Shares
94,200Holding current value
$476,651% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BCTX
# of Institutions
1Shares Held
1Call Options Held
0Put Options Held
0About BriaCell Therapeutics Corp.
- Ticker BCTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,518,000
- Market Cap $78.5M
- Description
- BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and...